Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

69.09 +0.89 (+1.31%)
Streaming Delayed Price Updated: 2:49 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%. 
Via Benzinga
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reeling
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Deal Dispatch: Bezos-Backed Crop Company Wilts, Tech Startup Nabs Napster For $207 Million
AT&T, Searchlight Capital Partners, Blackstone, I Squared Capital, and Morgan Stanley are all actively seeking to ink a deal. 
Via Benzinga
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates... 
Via Stocktwits
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion. 
Via Benzinga
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Via The Motley Fool
Topics Earnings
Exposures Financial Product Safety
Why Novo Nordisk Stock Dipped on Thursday
Via The Motley Fool
1 Growth Stock Down 40% to Buy and Hold Forever
Via The Motley Fool
Looking for growth without the hefty price tag? Consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO).
Based on Fundamental Analysis it can be said that NYSE:NVO is a growth stock which is not overvalued. 
Via Chartmill
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed. 
Via Benzinga
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management. 
Via Benzinga
Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you? 
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland... 
Via Stocktwits
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
There's a price war brewing in GLP-1 weight loss drugs, and now it's going global. 
Via The Motley Fool
Motley Fool 2025 March Market Cap Showdown Championship
Via The Motley Fool
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity and diabetes treatment. 
Via Benzinga
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Novo Nordisk is now planning to take on Eli Lilly's experimental retatrutide, a triple agonist for weight loss and diabetes. 
Via Investor's Business Daily
This Vanguard ETF Is Crushing the Market in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock 
Via MarketBeat
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
Via The Motley Fool
Is This Simple Index Fund a Millionaire Maker?
Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few opportunities and several challenges. 
Via The Motley Fool
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?
Via The Motley Fool
Why Novo Nordisk Stock Outpaced the Market on Tuesday
Via The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.